서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 15 of 15

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2005-01	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer Han, Sae-Won; Hwang, Pil Gyu; Chung, Doo Hyun; Kim, Dong-Wan; Im, Seock-Ah; Kim, Young Tae; Kim, Tae-You; Heo, Dae Seog; Bang, Yung-Jue; Kim, Noe Kyeong International Journal of Cancer, Vol.113 No.1, pp.109-115	DOI
2005-04	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib Han, Sae-Won; Kim, Tae-You; Hwang, Pil Gyu; Jeong, Soohyun; Kim, Jeongmi; Choi, In Sil; Oh, Do Youn; Kim, Jee Hyun; Kim, Dong-Wan; Chung, Doo Hyun; Im, Seock-Ah; Kim, Young Tae; Lee, Jong Seok; Heo, Dae Seog; Bang, Yung-Jue; Kim, Noe Kyeong Journal of Clinical Oncology, Vol.23 No.11, pp.2493-2501	DOI
2006-04	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation Han, Sae-Won; Kim, Tae-You; Jeon, Young Kyung; Hwang, Pil Gyu; Im, Seock-Ah; Lee, Kyung-Hun; Kim, Jee Hyun; Kim, Dong-Wan; Heo, Dae-Seog; Kim, Noe Kyeong; Chung, Doo Hyun; Bang, Yung-Jue Clinical Cancer Research, Vol.12 No.8, pp.2538-2544	DOI
2006-06	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer Lee, Kyung-Hun; Han, Sae-Won; Hwang, Pil Gyu; Oh, Do-Youn; Kim, Dong-Wan; Chung, Doo Hyun; Im, Seock-Ah; Kim, Tae-You; Heo, Dae Seog; Bang, Yung-Jue Japanese Journal of Clinical Oncology, Vol.36 No.6, pp.344-350	DOI
2006-11	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients Han, Sae-Won; Kim, Tae-You; Lee, Kyung-Hun; Hwang, Pil Gyu; Jeon, Yoon Kyung; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.54 No.2, pp.201-207	DOI
2009	Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Kim, Tae Won; Ryu, Min-Hee; Lee, Heungnam; Sym, Sun Jin; Lee, Jae-Lyun; Chang, Heung Moon; Park, Young Suk; Lee, Kyung Hee; Kang, Won Ki; Shin, Dong Bok; Bang, Yung-Jue; Lee, Jung Shin; Kang, Yoon-Koo Oncologist, Vol.14 No.5, pp.540-547	DOI
2009-04	A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor Ryu, Min-Hee; Kang, Won Ki; Bang, Yung-Jue; Lee, Kyung Hee; Shin, Dong Bok; Ryoo, Baek-Yeol; Roh, Jae Kyung; Kang, Jin-Hyoung; Lee, Hyoungnam; Kim, Tae Won; Chang, Heung Moon; Park, Joon Oh; Park, Young Suk; Kim, Tae-You; Kim, Min Kyoung; Lee, Woon Kee; Kang, Hye Jin; Kang, Yoon-Koo Oncology, Vol.76 No.5, pp.326-332	DOI
2011-06	Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization Im, Seock-Ah; Kim, Jin Won; Kim, Jin-Soo; Kim, Min A.; Jordan, Bruce; Pickl, Marlene; Han, Sae-Won; Oh, Do-Youn; Lee, Hyuk Joon; Kim, Tae-You; Kim, Woo Ho; Yang, Han-Kwang; Bang, Yung-Jue Diagnostic Molecular Pathology, Vol.20 No.2, pp.94-100	DOI
2012-07	MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome Lee, H. E.; Kim, M. A.; Lee, H. S.; Jung, E-J; Yang, H-K; Lee, B. L.; Bang, Y-J; Kim, W. H. British Journal of Cancer, Vol.107 No.2, pp.325-333	DOI
2013-01	Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation Kang, Yoon-Koo; Kang, Byung Woog; Im, Seock-Ah; Lee, Jae-Lyun; Park, Sook Ryun; Kang, Won Ki; Chang, Heung Moon; Kim, Tae Won; Oh, Do-Youn; Jung, Kyung Hae; Ryu, Min-Hee Cancer Chemotherapy and Pharmacology, Vol.71 No.1, pp.43-51	DOI
2015-10	Rise and fall of Kir2.2 current by TLR4 signaling in human monocytes: PKC-dependent trafficking and PI3K-mediated PIP2 decrease Kim, Kyung Soo; Jang, Ji Hyun; Lin, Haiyue; Choi, Seong Woo; Kim, Hang Rae; Shin, Dong Hoon; Nam, Joo Hyun; Zhang, Yin Hua; Kim, Sung Joon Journal of Immunology, Vol.195 No.7, pp.3345-3354	DOI
2016-03	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 alpha and STAT3 Koh, Jaemoon; Jang, Ji-Young; Keam, Bhumsuk; Kim, Sehui; Kim, Moon-Young; Go, Heounjeong; Kim, Tae Min; Kim, Dong-Wan; Kim, Chul-Woo; Jeon, Yoon Kyung; Chung, Doo Hyun OncoImmunology, Vol.5 No.3, p. e1108514	DOI
2016-09	Therapeutic implication of HER2 in advanced biliary tract cancer Nam, Ah-Rong; Kim, Ji-Won; Cha, Yongjun; Ha, Hyerim; Park, Ji Eun; Bang, Ju-Hee; Jin, Mei Hua; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue Oncotarget, Vol.7 No.36, pp.58007-58021	DOI
2017-12	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial ExteNET Study Group; Im, Seock Ah The Lancet Oncology, Vol.18 No.12, pp.1688-1700	DOI
2024-04	Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations Hong, David S.; Cappuzzo, Federico; Chul Cho, Byoung; Dowlati, Afshin; Hussein, Maen; Kim, Dong-Wan; Percent, Ivor; Christensen, James G.; Morin, Josée; Potvin, Diane; Faltaos, Demiana; Tassell, Vanessa; Der-Torossian, Hirak; Chao, Richard Lung Cancer, Vol.190, p. 107512	DOI

1